Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

37 results about "Impulse control disorder" patented technology

Impulse-control disorder (ICD) is a class of psychiatric disorders characterized by impulsivity – failure to resist a temptation, an urge, an impulse, or the inability to not speak on a thought. Many psychiatric disorders feature impulsivity, including substance-related disorders, behavioral addictions, attention deficit hyperactivity disorder, antisocial personality disorder, borderline personality disorder, conduct disorder and some mood disorders.

Combination Therapy

InactiveUS20080103179A1BiocideNervous disorderSYMPATHOMIMETIC AGENTSImpulse control disorder
The present invention features a novel therapy for treating diabetes, hypertension, migraine, epilepsy, sleep apnea, depression, impulse control disorders or alcohol addiction which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate compound (e.g., topiramate) or an anticonvulsive sulfonylurea compound (e.g. zonisamide).
Owner:VIVUS

Awareness enhancement and monitoring devices for the treatment of certain impulse control disorders

Apparatus for monitoring and discouraging trichotillomania and other unwanted behaviors includes a proximity detector, an event logger, and a user input facilitating event characterization. The proximity detector includes a sensor and an element associated with the arm, hand, finger, head or other user body part. The proximity detector is operative to generate an output signal in the event that the element has physically moved to within a predetermined distance relative to the sensor. The apparatus further includes a device operative to alert the user in response to the output signal generated by the proximity detector. Additional circuitry is provided enabling events to be examined and reviewed. Such circuitry would include a memory for storing information associated with alert events and an interface allowing the events to be examined and reviewed on a personal computer, for example. The provision of a real-time clock further enables date or time information to be stored in conjunction with an event. For additional insight into the events, an input may be provided allowing a user to characterize an event at the time of occurrence.
Owner:PERLMAN DAVID

Medicated spray for treatment of substance abuse, overdose, addiction and impulse control disorders

Provided herein are portable application devices and compositions for nasal and oral delivery of substances and compositions to treat overdose, addiction and / or behavioral disordered persons.
Owner:GOOBERMAN LANCE L

Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition

Selective norepinephrine reuptake inhibitors are useful for the prevention or treatment of hot flashes, vasomotor symptoms, impulse control disorders or personality change due to a general medical condition.
Owner:ELI LILLY & CO

Use of enantiomeric pure escitalopram

InactiveUS20040192765A1BiocideNervous disorderAcute Stress DisorderEscitalopram
The present invention relates to the use of anatiomeric pure escitalopram and / or of low dose medicaments thereof for the improved treatment of depression, in particular major depression disorder, neurotic disorders, acute stress disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, pre-mentrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder or drug abuse. The medicaments may also be used in the treatment of major depression disorder in "treatment resistant" patients.
Owner:H LUNDBECK AS

Andrographis Paniculata Compositions and Methods for Treatment of Addictions

Methods and compositions for the treatment or prevention of addictions and impulse control disorders using Andrographis paniculata, active substances contained therein and extracts thereof, alone or in combination with other therapeutic agents. The methods and compositions of the invention are useful in the treatment or prevention of addiction to substances, including alcohol, nicotine, marijuana, opioid agonists cocaine, and amphetamines, as well as impulse control disorders, including pathological gambling and pathological overeating.
Owner:OMEROS CORP

Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake

This invention provides a method for treating anxiety-related disorder or impulse control disorder, regulating food intake, attenuating food cravings, or treating anger and / or violence and disorders associated therewith in a patient, comprising administering to the patient in need thereof a therapeutically effective amount of ibogaine, ibogaine derivative, or a pharmaceutically acceptable salt and / or solvate thereof.
Owner:DEMERX

Impulse control disorder biological detection marker (Impulsins) and medical purpose of Impulsins

The invention provides an impulse control disorder biological detection marker (Impulsins) and a medical purpose of the Impulsins. The medical purpose belongs to application of an ATP enzyme ATP13A2 to preparation of a behavior and motion abnormality disease biological detection marker. The behavior and motion abnormality is caused by impulse control disorder and dyskinesia; and the amino acid sequence of ATP13A2 is shown as SEQ.No.1. The invention also provides application of sphingomyelin reduction and ceramide increase in blood due to APT enzyme ATP13A2 abnormality to preparation of an impulse control behavior and motion abnormality disease biological detection marker. The invention also provides application of a ceramide similar compound FTY720 or a sphingomyelinase inhibition compoundFluoxetine to preparation of medicine for treating impulse control behavior and motion abnormality diseases. Novel treatment medicine is provided for the behavior and motion abnormality diseases. Thetheoretical basis is provided for the clinic study of the behavior and motion abnormality diseases.
Owner:HANGZHOU DUANLI BIOTECH CO LTD

Methods and compositions for treating impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake

This invention provides a method for treating anxiety-related disorder or impulse control disorder, regulating food intake, attenuating food cravings, or treating anger and / or violence and disorders associated therewith in a patient, comprising administering to the patient in need thereof a therapeutically effective amount of noribogaine, noribogaine derivative, or a pharmaceutically acceptable salt and / or solvate thereof.
Owner:DEMERX

Treatment of impulsivity-related disorders

ActiveUS10653680B2Prevent relapseControl or treat impulsivity control disordersNervous disorderPharmaceutical delivery mechanismMood instabilityControl disorders
The invention relates to the treatment of impulsivity-related disorders, such as a substance-related addiction, a behavioural addiction, relapse to a substance-related or behavioural addiction, a habit or impulsive disorder, an emotional unstable personality disorder, intentional self harm, an eating disorder, a dopamine agonist-induced impulse control disorder, or attention deficit hyperactivity disorder (ADHD) by administering a compound of Formula I or a salt thereof to a subject; Formula (I) wherein: E is S or Se; R1 and R2 are optional substituents, and are at each occurrence independently selected from: (1) a halogen, which is preferably selected from F, CI and Br; (2) C1-C4 alkyl, such as C1-C2 alkyl or C1 alkyl, optionally substituted with one or more halogen atoms, each of which is preferably selected from F, CI and Br; and (3) C1-C4 alkoxy, such as C1-C2 alkoxy or C1 alkoxy; optionally substituted with one or more halogen atoms, each of which is preferably selected from F, CI and Br; m is an integer in the range of from 0 to 5; and n is an integer in the range of from 0 to 4. The compound can also be used to treat or control impulsivity control disorders in patients undergoing dopamine agonist treatment, for example in patients suffering from Parkinson's disease or ADFID.
Owner:OXFORD UNIV INNOVATION LTD

Treatment of impulsivity-related disorders

ActiveUS20190111029A1Prevent relapseControl or treat impulsivity control disordersNervous disorderPharmaceutical delivery mechanismDiseaseControl disorders
The invention relates to the treatment of impulsivity-related disorders, such as a substance-related addiction, a behavioural addiction, relapse to a substance-related or behavioural addiction, a habit or impulsive disorder, an emotional unstable personality disorder, intentional self harm, an eating disorder, a dopamine agonist-induced impulse control disorder, or attention deficit hyperactivity disorder (ADHD) by administering a compound of Formula I or a salt thereof to a subject; Formula (I) wherein: E is S or Se; R1 and R2 are optional substituents, and are at each occurrence independently selected from: (1) a halogen, which is preferably selected from F, CI and Br; (2) C1-C4 alkyl, such as C1-C2 alkyl or C1 alkyl, optionally substituted with one or more halogen atoms, each of which is preferably selected from F, CI and Br; and (3) C1-C4 alkoxy, such as C1-C2 alkoxy or C1 alkoxy; optionally substituted with one or more halogen atoms, each of which is preferably selected from F, CI and Br; m is an integer in the range of from 0 to 5; and n is an integer in the range of from 0 to 4. The compound can also be used to treat or control impulsivity control disorders in patients undergoing dopamine agonist treatment, for example in patients suffering from Parkinson's disease or ADFID.
Owner:OXFORD UNIV INNOVATION LTD

System and Method for Assessing Impulse Control Disorder

A method of assessing the likelihood that an individual has impulse control disorder. The individual is provided with an actuator, and instructed to actuate the actuator as an acknowledgement of when the individual has completed a reward task. Actuation of the actuator is monitored and recorded. An automated diagnosis of ICD is produced and output, wherein a greater degree of actuation of the actuator by the individual is taken to indicate a greater likelihood that the individual has impulse control disorder.
Owner:GLOBAL KINETICS PTY LTD

Treating impulse control disorders with catechol-o-methyl-transferase inhibitors

ActiveUS20120004316A1BiocideNervous disorderCatechol-O-methyl transferaseImpulse control disorder
The invention provides methods for treating impulse control disorders in patients with catechol-o-methyl-transferase inhibitors. The invention also provides methods for treating patients with obsessive compulsive disorders and substance addictions with catechol-o-methyl-transferase inhibitors.
Owner:GRANT JON E
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products